Resistance mechanism for ibrutinib in marginal zone lymphoma

Blood Adv. 2019 Feb 26;3(4):500-502. doi: 10.1182/bloodadvances.2018029058.

Abstract

  1. The molecular events leading to primary and acquired resistance to ibrutinib in marginal zone lymphoma have not been studied.

  2. We describe the first case of MZL with acquired resistance to ibrutinib in which mutations in both BTK (C481S) and PLCG2 are documented.

Publication types

  • Case Reports

MeSH terms

  • Adenine / analogs & derivatives
  • Agammaglobulinaemia Tyrosine Kinase / antagonists & inhibitors
  • Aged
  • Bone Marrow / drug effects
  • Bone Marrow / pathology
  • Drug Resistance, Neoplasm*
  • Humans
  • Lymphoma, B-Cell, Marginal Zone / drug therapy*
  • Lymphoma, B-Cell, Marginal Zone / pathology
  • Male
  • Piperidines
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrazoles / pharmacology
  • Pyrazoles / therapeutic use*
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use*

Substances

  • Piperidines
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • ibrutinib
  • Agammaglobulinaemia Tyrosine Kinase
  • BTK protein, human
  • Adenine